secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-020831
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical Q1 net loss $9.3M; Phase 2b ODYSSEY trial to open Q2 2023
------------------------------------------------------------------------------

- Net loss of $9.3M ($0.15 per share) vs $7.6M ($0.13) in Q1 2022.
- Cash and equivalents $41.4M; company expects to fund operations into Q2 2024.
- R&D expenses flat at $4.5M; G&A down to $3.2M from $3.5M.
- Phase 2b ODYSSEY trial of CLS-AX in wet AMD to open enrollment Q2 2023; topline results expected Q3 2024.
- Positive safety and duration data from OASIS Phase 1/2a extension study presented at ARVO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023020831/0000950170-23-020831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023020831/clsd-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer